Probiotics and Hemodynamic Changes in Cirrhosis

• Status: Active, not recruiting
• Trial end date: 2022-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center blinded randomized interventional placebo-controlled study of the effect of probiotics on hemodynamic parameters and liver function in cirrhosis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: I.M. Sechenov First Moscow State Medical University

Criteria

Inclusion Criteria:

• Cirrhosis

• Child-Pugh class B or C;

• Age between 18 and 70 years;

• Signed informed consent.

Exclusion Criteria:

• Use of lactulose, lactitol, or other prebiotics, probiotics, antibiotics, or metformin in the past 6 weeks before inclusion;

• Alcohol consumption in the past 6 weeks before inclusion;

• Inflammatory bowel disease;

• Cancer;

• Prematurely discontinuation of the consumption of tested probiotic/placebo;

• Started taking antibiotics, other probiotics, or prebiotics during the follow-up period;

• Refusal to participate during the follow-up period.